Antisense oligonucleotides are reshaping drug design, from RNase H gapmers to inhaled delivery; this FAQ explains how they work and why trials still fail.
|Articles|September 15, 2017
Glass Vials for Biologic Injectables
Author(s)BioPharm International Editors
Bormioli Rocco Pharma, an Italian supplier of glass and plastic packaging, has launched its Delta-molded, type 1 glass vials in North America.
Advertisement
Bormioli Rocco Pharma, an Italian supplier of glass and plastic packaging, has made its Delta-molded, type 1 glass vials available to the North American market. The vials are available in a range of sizes and capabilities for injectables, including biologics, and offer high hydrolytic resistance and internal surface homogeneity to protect against delamination and ensure product stability.
Source:
Advertisement
Related to this article
Bristol Myers Squibb's Nathan Pennell explains how the MRD endpoint supports accelerated approval in multiple myeloma without changing how clinicians monitor patients.
Teprotumumab N01 (Sycume) reduced eye bulging in 60.4% of patients with chronic, inactive thyroid eye disease in a phase 3 trial.
Caribou is halting vispa-cel and CB-011, allogeneic CAR-T therapies that showed up to 92% response rates, citing a difficult financing environment.
Manufacturing remediation, not efficacy or safety data, is delaying US approval of Novo's h+emophilia A therapy denecimig.
Doubled drug substance capacity at Alvotech's Reykjavik, Iceland, site aims to secure steady US supply of the Humira biosimilar Simlandi.
Artiva Biotherapeutics will present data on AlloNK, an allogeneic, non-genetically modified NK cell therapy given with rituximab, in refractory rheumatoid arthritis, Sjögren disease and systemic sclerosis at ACR Convergence 2026, ahead of a planned phase 3 trial in rheumatoid arthritis.
The 15-month project could let living cell therapies ship and store at room temperature, cutting cold-chain costs that limit patient access.
Advertisement
Advertisement